Reviewing ProMetic Life Sciences (OTCMKTS:PFSCF) & AB Corporate Bond ETF (NASDAQ:EYEG)

Valuation and Earnings

This table compares ProMetic Life Sciences and AB Corporate Bond ETF”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A
AB Corporate Bond ETF	$12,059.00	2,349.45	-$8.09 million	($1.68)	-21.08

AB Corporate Bond ETF has lower revenue, but higher earnings than ProMetic Life Sciences.

Volatility & Risk

ProMetic Life Sciences has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, AB Corporate Bond ETF has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. Comparatively, 64.2% of AB Corporate Bond ETF shares are owned by institutional investors. 58.2% of AB Corporate Bond ETF shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares ProMetic Life Sciences and AB Corporate Bond ETF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%
AB Corporate Bond ETF	N/A	-104.96%	-60.03%

Summary

AB Corporate Bond ETF beats ProMetic Life Sciences on 7 of the 9 factors compared between the two stocks.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.